caa a22 4500 477057365 CHVBK 20180405111350.0 cr unu---uuuuu 170330e19960601xx s 000 0 eng 10.1007/s002280050110 doi (NATIONALLICENCE)springer-10.1007/s002280050110 Pharmacokinetics of flosequinan in patients with heart failure [Elektronische Daten] [D. P. Nicholls, A. Droogan, C. A. Carson, I. C. Taylor, A. P. Passmore, G. D. Johnston, M. Kendall, D. Dutka, G. K. Morris, L. M. Underwood, I. D. Hind] Objective: The pharmacokinetics of flosequinan were studied in a group of 18 patients with chronic cardiac failure. Results: After a single dose of 100 mg, Cmax of the parent compound (2.52 mg ⋅ l−1) was recorded at 1.4 h, and of the sulphone metabolite flosequinoxan at 21.7 h. The plasma elimination half lives of the parent compound (6.4 h) and of the metabolite (54.3 h) were prolonged compared to previous studies in normal volunteers. After repeated dose administration for 36 days, the kinetics of the parent compound and metabolite remained essentially unchanged with an expected significant accumulation of metabolite (Cmax 8.4 vs 3.21 mg ⋅ l−1). No adverse effects were observed. Conclusion: It is possible that altered drug kinetics in patients with heart failure, probably related to altered hepatic blood flow, could contribute to drug toxicity. Springer-Verlag Berlin Heidelberg, 1996 Key words Heart failure nationallicence Flosequinan nationallicence pharmacokinetics nationallicence drug toxicity nationallicence Nicholls D. P. Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, IE aut Droogan A. Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, IE aut Carson C. A. Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, IE aut Taylor I. C. Ulster Hospital, Dundonald, Belfast, XX aut Passmore A. P. City Hospital, Belfast, XX aut Johnston G. D. City Hospital, Belfast, XX aut Kendall M. Queen Elizabeth Hospital, Birmingham, XX aut Dutka D. City Hospital, Nottingham, XX aut Morris G. K. City Hospital, Nottingham, XX aut Underwood L. M. Knoll Pharmaceuticals, Nottingham, XX aut Hind I. D. Knoll Pharmaceuticals, Nottingham, XX aut https://doi.org/10.1007/s002280050110 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050110 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nicholls D. P. Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, IE aut NATIONALLICENCE 700 1- Droogan A. Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, IE aut NATIONALLICENCE 700 1- Carson C. A. Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, IE aut NATIONALLICENCE 700 1- Taylor I. C. Ulster Hospital, Dundonald, Belfast, XX aut NATIONALLICENCE 700 1- Passmore A. P. City Hospital, Belfast, XX aut NATIONALLICENCE 700 1- Johnston G. D. City Hospital, Belfast, XX aut NATIONALLICENCE 700 1- Kendall M. Queen Elizabeth Hospital, Birmingham, XX aut NATIONALLICENCE 700 1- Dutka D. City Hospital, Nottingham, XX aut NATIONALLICENCE 700 1- Morris G. K. City Hospital, Nottingham, XX aut NATIONALLICENCE 700 1- Underwood L. M. Knoll Pharmaceuticals, Nottingham, XX aut NATIONALLICENCE 700 1- Hind I. D. Knoll Pharmaceuticals, Nottingham, XX aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer